Concurrent pituitary apoplexy and posterior reversible encephalopathy syndrome in a patient with end-stage renal disease on hemodialysis: A case report

Rationale: Pituitary apoplexy (PA) and posterior reversible encephalopathy syndrome (PRES) are rare neurologic diseases that show acute neuro-ophthalmologic symptoms such as headache, decreased visual acuity, and altered consciousness. These diseases are rarely found in patients with end-stage renal disease (ESRD) on hemodialysis, and simultaneous occurrence of these 2 diseases has not been reported. Patient concerns: The patient was a 75-year-old man with a history of hypertension, diabetes mellitus, and non-functioning pituitary macroadenoma. He had been receiving hemodialysis for ESRD for 3 months before his presentation to the emergency room. The patient complained of headache, vomiting, and dizziness that started after the previous day's hemodialysis. The patient had voluntarily discontinued his antihypertensive medication 2 weeks before presentation and had high blood pressure with marked fluctuation during hemodialysis. Complete ptosis and ophthalmoplegia on the right side suggested 3rd, 4th, and 6th cranial nerve palsies. Diagnoses: Magnetic resonance imaging of the brain revealed a pituitary tumor, intratumoral hemorrhage within the sella, and symmetric vasogenic edema in the subcortical white matter in the parieto-occipital lobes. Based on these findings, the patient was diagnosed with PA and PRES. Interventions: Intravenous administration of hydrocortisone (50 mg every 6 hours after a bolus administration of 100 mg) was initiated. Although surgical...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Related Links:

Publication date: Available online 30 May 2020Source: Journal of American Association for Pediatric Ophthalmology and StrabismusAuthor(s): Gamze Dereli Can, Muhammet Furkan Korkmaz, Mehmet Erol Can
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - Category: Opthalmology Source Type: research
Publication date: Available online 30 May 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Jia-Kang Wang, Tzu-Lun Huang, Pei-Yao Chang
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Publication date: Available online 31 May 2020Source: American Journal of Infection ControlAuthor(s): Johanna M. Vanegas, Lorena Salazar-Ospina, Gustavo Roncancio, J Natalia Jiménez
Source: American Journal of Infection Control - Category: Infectious Diseases Source Type: research
Publication date: Available online 30 May 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Hema S. Gopalan, Anoop Misra
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 30 May 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Sachin Atre, Sona Deshmukh, Manjusha Kulkarni
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: 15 September 2020Source: Journal of Ethnopharmacology, Volume 259Author(s): Junnan Ma, Xianglong Meng, Yi Liu, Cheng Yin, Tong Zhang, Piao Wang, Yong-Ki Park, Hyo Won Jung
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Osborne H Abstract The calcium-sensing receptor (CaSR) is a class C G protein-coupled receptor that responds to multiple endogenous agonists and allosteric modulators, including divalent and trivalent cations, L-amino acids, γ-glutamyl peptides, polyamines, polycationic peptides, and protons. The CaSR plays a critical role in extracellular calcium (Ca2+ o) homeostasis, as demonstrated by the many naturally occurring mutations in the CaSR or its signaling partners that cause Ca2+ o homeostasis disorders. However, CaSR tissue expression in mammals is broad and includes tissues unrelated to Ca2+ o homeostasis, ...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Pharmacol Rev Source Type: research
Publication date: July 2020Source: American Heart Journal, Volume 225Author(s): Angela Lowenstern, Shuang Li, Salim S. Virani, Ann Marie Navar, Zhuokai Li, Jennifer G. Robinson, Veronique L. Roger, Anne C. Goldberg, Andrew Koren, Michael J. Louie, Eric D. Peterson, Tracy Y. Wang
Source: American Heart Journal - Category: Cardiology Source Type: research
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Authors: Infusino F, Cimino S, Lombardi M, Mancone M, Cavarretta E, Frati G, Pugliese F, Fedele F, Biondi-Zoccai G Abstract SARS-CoV-2 is spreading rapidly all over the world. The case fatality rate seems higher in cardiovascular disease and hypertension. Other comorbidities do not seem to confer the same risk, therefore the understanding of the relationship between infection and cardiovascular system could be a crucial point for the fight against the virus. A great interest is currently directed towards the angiotensin 2 converting enzyme (ACE 2) which is the SARS-CoV-2 receptor and creates important connections b...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
More News: Brain | Brain Cancers | Diabetes | Diabetes Mellitus | Dialysis | Emergency Medicine | Endocrinology | Headache | Hemodialysis | Hemorrhagic Stroke | Hydrocortisone | Hypertension | Internal Medicine | Lessons | Migraine | MRI Scan | Neurology | Neurosurgery | Opthalmology | Pituitary Tumor | Prednisolone